Clinical Trial Update: Effect of MK0524A on Flushing Caused by Niacin (0524A-056) [Phase 3]

View source ↗

Summary

Phase 3 study assessing MK0524A for reducing flushing caused by niacin; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Flushing

Drugs mentioned

• MK0524A

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Flushing | Phase 3 | Status: COMPLETED